Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07431177
PHASE2

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period

Key Details

Gender

All

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2026-03-09

Completion Date

2030-02-14

Last Updated

2026-04-06

Healthy Volunteers

No

Interventions

DRUG

GIA632

GIA632 will be administered during the 48-week core period.

DRUG

Placebo

Placebo will be administered during the 48-week core period.

Locations (10)

Cahaba Derm and skin hlth ctr 27

Birmingham, Alabama, United States

Clinical Trials Research Institute

Thousand Oaks, California, United States

Miami Derm and Laser Institute

Miami, Florida, United States

Dawes Fretzin Clinical Rea Group

Indianapolis, Indiana, United States

Revival Research Institute

Troy, Michigan, United States

Austin Inst for Clinical Research

Pflugerville, Texas, United States

Novartis Investigative Site

Sydney, New South Wales, Australia

Novartis Investigative Site

Waitara, New South Wales, Australia

Novartis Investigative Site

Mississauga, Ontario, Canada

Novartis Investigative Site

Toronto, Ontario, Canada